{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T09:47:47Z","timestamp":1791971267212,"version":"4.3.4"},"reference-count":141,"publisher":"Informa UK Limited","license":[{"start":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T00:00:00Z","timestamp":1791936000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"},{"start":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T00:00:00Z","timestamp":1791936000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/doi.org\/10.1080\/policies-text-data-mining"}],"funder":[{"DOI":"10.13039\/100008730","name":"Kreftforeningen","doi-asserted-by":"publisher","award":["297210"],"award-info":[{"award-number":["297210"]}],"id":[{"id":"10.13039\/100008730","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Expert Opinion on Therapeutic Targets"],"DOI":"10.1080\/14728222.2026.2748740","type":"journal-article","created":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T11:31:44Z","timestamp":1791891104000},"page":"1-17","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":0,"title":["Molecular basis for developing tumor-targeted siRNAs for future immunotherapy"],"prefix":"10.1080","author":[{"given":"Mouldy","family":"Sioud","sequence":"first","affiliation":[{"name":"Oslo University Hospital- Radiumhospitalet","place":["Oslo, Norway"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2026,10,14]]},"reference":[{"key":"e_1_3_4_3_1","doi-asserted-by":"publisher","DOI":"10.1038\/35888"},{"key":"e_1_3_4_4_1","doi-asserted-by":"publisher","DOI":"10.1038\/35078107"},{"key":"e_1_3_4_5_1","doi-asserted-by":"publisher","DOI":"10.1038\/418244a"},{"key":"e_1_3_4_6_1","doi-asserted-by":"publisher","DOI":"10.1038\/nature02873"},{"key":"e_1_3_4_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2005.08.044"},{"key":"e_1_3_4_8_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrm2632"},{"key":"e_1_3_4_9_1","doi-asserted-by":"publisher","DOI":"10.1007\/978-1-0716-4742-4-1"},{"key":"e_1_3_4_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bioadv.2024.214120"},{"issue":"21","key":"e_1_3_4_11_1","doi-asserted-by":"crossref","first-page":"2697","DOI":"10.1111\/bph.15972","article-title":"Small interfering RNA: discovery, pharmacology and clinical development-an introductory review","volume":"180","author":"Ranasinghe P","year":"2023","unstructured":"Ranasinghe P, Addison ML, Dear JW, et al. Small interfering RNA: discovery, pharmacology and clinical development-an introductory review. Br J Pharmacol. 2023;180(21):2697\u20132720.","journal-title":"Br J Pharmacol"},{"key":"e_1_3_4_12_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41588-018-0104-1"},{"key":"e_1_3_4_13_1","doi-asserted-by":"publisher","DOI":"10.3390\/molecules25112692"},{"key":"e_1_3_4_14_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-020-0207-x"},{"key":"e_1_3_4_15_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-55721-w"},{"key":"e_1_3_4_16_1","doi-asserted-by":"publisher","DOI":"10.1021\/bi00495a001"},{"key":"e_1_3_4_17_1","doi-asserted-by":"publisher","DOI":"10.1038\/nbt.3765"},{"key":"e_1_3_4_18_1","doi-asserted-by":"publisher","DOI":"10.1111\/cts.70536"},{"key":"e_1_3_4_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2016.10.019"},{"key":"e_1_3_4_20_1","doi-asserted-by":"publisher","DOI":"10.1089\/nat.2018.0736"},{"key":"e_1_3_4_21_1","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1007\/978-1-0716-4742-4_3","article-title":"Chemical modifications in nucleic acid therapeutics","volume":"2965","author":"Lennox KA","year":"2025","unstructured":"Lennox KA, Young RC, Behlke MA. Chemical modifications in nucleic acid therapeutics. Methods Mol Biol. 2025;2965:57\u2013126.","journal-title":"Methods Mol Biol"},{"key":"e_1_3_4_22_1","doi-asserted-by":"publisher","DOI":"10.1038\/mt.2011.263"},{"key":"e_1_3_4_23_1","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/gkw236"},{"key":"e_1_3_4_24_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1609243"},{"key":"e_1_3_4_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.omtn.2026.102865"},{"key":"e_1_3_4_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbrc.2003.11.057"},{"key":"e_1_3_4_27_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jmb.2005.03.013"},{"key":"e_1_3_4_28_1","doi-asserted-by":"publisher","DOI":"10.1038\/nbt1081"},{"key":"e_1_3_4_29_1","doi-asserted-by":"publisher","DOI":"10.1038\/nm1191"},{"key":"e_1_3_4_30_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.molmed.2006.02.004"},{"key":"e_1_3_4_31_1","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/gkaa670"},{"key":"e_1_3_4_32_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-45609-0"},{"key":"e_1_3_4_33_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2567.2009.03093.x"},{"key":"e_1_3_4_34_1","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/gkad268"},{"key":"e_1_3_4_35_1","doi-asserted-by":"publisher","DOI":"10.36849\/JDD.6384"},{"key":"e_1_3_4_36_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-25-3189"},{"key":"e_1_3_4_37_1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1501679"},{"issue":"11","key":"e_1_3_4_38_1","doi-asserted-by":"crossref","first-page":"2402","DOI":"10.1158\/1078-0432.CCR-23-3029","article-title":"A first-in-human phase 1 study of a tumor-directed RNA-interference drug against HIF2\u03b1 in patients with advanced clear-cell renal cell carcinoma","volume":"30","author":"Brugarolas J","year":"2024","unstructured":"Brugarolas J, Obara G, Beckermann KE, et al. A first-in-human phase 1 study of a tumor-directed RNA-interference drug against HIF2\u03b1 in patients with advanced clear-cell renal cell carcinoma. Clin Cancer Res. 2024;30(11):2402\u20132411.","journal-title":"Clin Cancer Res"},{"key":"e_1_3_4_39_1","doi-asserted-by":"publisher","DOI":"10.1084\/jem.182.2.459"},{"key":"e_1_3_4_40_1","doi-asserted-by":"publisher","DOI":"10.1038\/nri1349"},{"key":"e_1_3_4_41_1","doi-asserted-by":"publisher","DOI":"10.1093\/intimm\/8.5.765"},{"key":"e_1_3_4_42_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12094-024-03835-4"},{"key":"e_1_3_4_43_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2024.01.010"},{"key":"e_1_3_4_44_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-065X.2008.00662.x"},{"issue":"1","key":"e_1_3_4_45_1","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1111\/j.1600-065X.2009.00769.x","article-title":"Yin-Yang of costimulation: crucial controls of immune tolerance and function","volume":"229","author":"Nurieva RI","year":"2009","unstructured":"Nurieva RI, Liu X, Dong C. Yin-Yang of costimulation: crucial controls of immune tolerance and function. Immunol Rev. 2009;229(1):88\u2013100.","journal-title":"Immunol Rev"},{"key":"e_1_3_4_46_1","doi-asserted-by":"publisher","DOI":"10.1155\/jimr\/7864229"},{"key":"e_1_3_4_47_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2017.02.008"},{"key":"e_1_3_4_48_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1910549"},{"key":"e_1_3_4_49_1","doi-asserted-by":"publisher","DOI":"10.1126\/science.aad0095"},{"key":"e_1_3_4_50_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2020.08.007"},{"key":"e_1_3_4_51_1","doi-asserted-by":"publisher","DOI":"10.1080\/14712598.2023.2183116"},{"key":"e_1_3_4_52_1","doi-asserted-by":"publisher","DOI":"10.4161\/hv.29754"},{"issue":"8","key":"e_1_3_4_53_1","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1007\/s00262-010-0842-0","article-title":"RNA interference targeting programmed death receptor-1 improves immune functions of tumor-specific T cells","volume":"59","author":"Borkner L","year":"2010","unstructured":"Borkner L, Curham LM, Wilk MM. RNA interference targeting programmed death receptor-1 improves immune functions of tumor-specific T cells. Cancer Immunol Immunother. 2010;59(8):1173\u20131183.","journal-title":"Cancer Immunol Immunother"},{"key":"e_1_3_4_54_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2018.04.015"},{"key":"e_1_3_4_55_1","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-003928"},{"key":"e_1_3_4_56_1","doi-asserted-by":"publisher","DOI":"10.1039\/D0BM00908C"},{"key":"e_1_3_4_57_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-04-278739"},{"key":"e_1_3_4_58_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-015-1668-6"},{"issue":"4","key":"e_1_3_4_59_1","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1097\/CJI.0000000000000071","article-title":"Efficient nontoxic delivery of PD-L1 and PD-L2 siRNA into dendritic cell vaccines using the cationic lipid SAINT-18","volume":"38","author":"Roeven MW","year":"2015","unstructured":"Roeven MW, Hobo W, van der Voort R, et al. Efficient nontoxic delivery of PD-L1 and PD-L2 siRNA into dendritic cell vaccines using the cationic lipid SAINT-18. J Immunother. 2015;38(4):145\u2013154.","journal-title":"J Immunother"},{"issue":"8","key":"e_1_3_4_60_1","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1158\/2326-6066.CIR-16-0336","article-title":"Monocyte-derived dendritic cells with silenced PD-1 ligands and transpresenting interleukin-15 stimulate strong tumor-reactive T cell expansion","volume":"5","author":"Van den Bergh JMJ","year":"2017","unstructured":"Van den Bergh JMJ, Smits ELJM, Berneman ZN, et al. Monocyte-derived dendritic cells with silenced PD-1 ligands and transpresenting interleukin-15 stimulate strong tumor-reactive T cell expansion. Cancer Immunol Res. 2017;5(8):710\u2013715.","journal-title":"Cancer Immunol Res"},{"key":"e_1_3_4_61_1","doi-asserted-by":"publisher","DOI":"10.1002\/adhm.201500089"},{"key":"e_1_3_4_62_1","doi-asserted-by":"publisher","DOI":"10.2217\/nnm-2018-0237"},{"issue":"46","key":"e_1_3_4_63_1","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1016\/j.jconrel.2022.04.023","article-title":"PD-L1 siRNA-hyaluronic acid conjugate for dual-targeted cancer immunotherapy","volume":"3","author":"Kim S","year":"2022","unstructured":"Kim S, Heo R, Song SH, et al. PD-L1 siRNA-hyaluronic acid conjugate for dual-targeted cancer immunotherapy. J Control Release. 2022;3(46):226\u2013239.","journal-title":"J Control Release"},{"key":"e_1_3_4_64_1","doi-asserted-by":"publisher","DOI":"10.1002\/jbm.b.34516"},{"key":"e_1_3_4_65_1","doi-asserted-by":"publisher","DOI":"10.1021\/acsami.1c21775"},{"key":"e_1_3_4_66_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijpharm.2026.126917"},{"key":"e_1_3_4_67_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bioadv.2023.213425"},{"key":"e_1_3_4_68_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12951-025-03521-9"},{"key":"e_1_3_4_69_1","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.aax5032"},{"key":"e_1_3_4_70_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jconrel.2016.01.044"},{"key":"e_1_3_4_71_1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.931316"},{"key":"e_1_3_4_72_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygeno.2023.110646"},{"key":"e_1_3_4_73_1","doi-asserted-by":"publisher","DOI":"10.1021\/acsnano.2c10797"},{"key":"e_1_3_4_74_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.mtbio.2022.100350"},{"key":"e_1_3_4_75_1","doi-asserted-by":"publisher","DOI":"10.1002\/adma.202412141"},{"key":"e_1_3_4_76_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-025-14830-5"},{"key":"e_1_3_4_77_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2021.108288"},{"key":"e_1_3_4_78_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-024-03835-x"},{"key":"e_1_3_4_79_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-15-2626"},{"issue":"16","key":"e_1_3_4_80_1","doi-asserted-by":"crossref","first-page":"7522","DOI":"10.1200\/JCO.2022.40.16_suppl.7522","article-title":"Phase 1\/2 study of anbalcabtagene autoleucel, novel anti-CD19 CAR-T therapy with dual silencing of PD-1 and TIGIT in relapsed or refractory large B-cell lymphoma","volume":"40","author":"Kim WS","year":"2022","unstructured":"Kim WS, Kim SJ, Yoon SE, et al. Phase 1\/2 study of anbalcabtagene autoleucel, novel anti-CD19 CAR-T therapy with dual silencing of PD-1 and TIGIT in relapsed or refractory large B-cell lymphoma. J Clin Oncol. 2022;40(16_suppl):7522. (conference abstract\/proceedings).","journal-title":"J Clin Oncol"},{"issue":"6","key":"e_1_3_4_81_1","doi-asserted-by":"crossref","first-page":"0436","DOI":"10.34133\/cbsystems.0436","article-title":"Carrier-free peptide-daunorubicin-small interfering RNA nanoassembly for targeted therapy of acute myeloid leukemia","volume":"5","author":"Yang H","year":"2025","unstructured":"Yang H, Yu X, Guo Z, et al. Carrier-free peptide-daunorubicin-small interfering RNA nanoassembly for targeted therapy of acute myeloid leukemia. Cyborg Bionic Syst. 2025;5(6):0436.","journal-title":"Cyborg Bionic Syst"},{"key":"e_1_3_4_82_1","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2015.1016700"},{"key":"e_1_3_4_83_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-026-02583-z"},{"key":"e_1_3_4_84_1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.636081"},{"key":"e_1_3_4_85_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.biomaterials.2014.02.003"},{"key":"e_1_3_4_86_1","doi-asserted-by":"publisher","DOI":"10.3390\/ijms26031196"},{"key":"e_1_3_4_87_1","doi-asserted-by":"publisher","DOI":"10.1021\/acs.molpharmaceut.5c00715"},{"key":"e_1_3_4_88_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-011-1188-y"},{"key":"e_1_3_4_89_1","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-11-3850"},{"key":"e_1_3_4_90_1","doi-asserted-by":"publisher","DOI":"10.1021\/nn500216y"},{"key":"e_1_3_4_91_1","doi-asserted-by":"publisher","DOI":"10.3390\/ph15121487"},{"issue":"5","key":"e_1_3_4_92_1","doi-asserted-by":"crossref","first-page":"e10392","DOI":"10.1002\/btm2.10392","article-title":"Shaping the \u201chot\u201d immunogenic tumor microenvironment by nanoparticles co-delivering oncolytic peptide and TGF-\u03b21 siRNA for boosting checkpoint blockade therapy","volume":"8","author":"Phung CD","year":"2022","unstructured":"Phung CD, Nguyen BL, Jeong JH, et al. Shaping the \u201chot\u201d immunogenic tumor microenvironment by nanoparticles co-delivering oncolytic peptide and TGF-\u03b21 siRNA for boosting checkpoint blockade therapy. Bioeng Transl Med. 2022;8(5):e10392.","journal-title":"Bioeng Transl Med"},{"key":"e_1_3_4_93_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.biomaterials.2023.122253"},{"key":"e_1_3_4_94_1","doi-asserted-by":"publisher","DOI":"10.1093\/narcan\/zcad059"},{"key":"e_1_3_4_95_1","doi-asserted-by":"publisher","DOI":"10.2217\/nnm-2022-0257"},{"key":"e_1_3_4_96_1","doi-asserted-by":"publisher","DOI":"10.1111\/cns.14489"},{"key":"e_1_3_4_97_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12026-011-8262-6"},{"key":"e_1_3_4_98_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clim.2007.11.011"},{"key":"e_1_3_4_99_1","doi-asserted-by":"publisher","DOI":"10.1097\/CJI.0b013e3181e5c278"},{"key":"e_1_3_4_100_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jconrel.2011.06.008"},{"key":"e_1_3_4_101_1","first-page":"13","article-title":"T-cell activation is enhanced by targeting IL-10 cytokine production in toll-like receptor-stimulated macrophages","volume":"1","author":"Walk RM","year":"2012","unstructured":"Walk RM, Elliott ST, Blanco FC, et al. T-cell activation is enhanced by targeting IL-10 cytokine production in toll-like receptor-stimulated macrophages. ImmunoTargets Ther. 2012;1:13\u201323.","journal-title":"ImmunoTargets Ther"},{"key":"e_1_3_4_102_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.biomaterials.2014.03.039"},{"key":"e_1_3_4_103_1","first-page":"5981","article-title":"Sequential delivery of an anticancer drug and combined immunomodulatory nanoparticles for efficient chemoimmunotherapy","volume":"10","author":"Heo MB","year":"2015","unstructured":"Heo MB, Kim SY, Yun WS, et al. Sequential delivery of an anticancer drug and combined immunomodulatory nanoparticles for efficient chemoimmunotherapy. Int J Nanomed. 2015;10:5981\u20135992.","journal-title":"Int J Nanomed"},{"key":"e_1_3_4_104_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jconrel.2021.08.031"},{"key":"e_1_3_4_105_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-016-1905-7"},{"key":"e_1_3_4_106_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.it.2016.01.002"},{"key":"e_1_3_4_107_1","doi-asserted-by":"publisher","DOI":"10.1097\/CJI.0000000000000022"},{"key":"e_1_3_4_108_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-019-47799-w"},{"key":"e_1_3_4_109_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jconrel.2018.01.013"},{"key":"e_1_3_4_110_1","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.31588"},{"key":"e_1_3_4_111_1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.00968"},{"key":"e_1_3_4_112_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-08-1988"},{"key":"e_1_3_4_113_1","doi-asserted-by":"publisher","DOI":"10.3892\/ijo.2013.1922"},{"key":"e_1_3_4_114_1","doi-asserted-by":"publisher","DOI":"10.1155\/2016\/9639585"},{"key":"e_1_3_4_115_1","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.27710"},{"key":"e_1_3_4_116_1","doi-asserted-by":"publisher","DOI":"10.1038\/ni1012"},{"issue":"3","key":"e_1_3_4_117_1","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1080\/08830185.2023.2274576","article-title":"Stats signalling pathways in dendritic cells: As potential therapeutic targets?","volume":"43","author":"Sohrabi S","year":"2024","unstructured":"Sohrabi S, Masoumi J, Naseri B, et al. Stats signalling pathways in dendritic cells: As potential therapeutic targets? Int Rev Immunol. 2024;43(3):138\u2013159.","journal-title":"Int Rev Immunol"},{"key":"e_1_3_4_118_1","doi-asserted-by":"publisher","DOI":"10.1038\/nbt1035"},{"issue":"1","key":"e_1_3_4_119_1","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1172\/JCI26169","article-title":"SOCS1 restricts dendritic cells\u2019 ability to break self-tolerance and induce antitumor immunity by regulating IL-12 production and signalling","volume":"116","author":"Evel-Kabler K","year":"2006","unstructured":"Evel-Kabler K, Song X-T, Aldrich M, et al. SOCS1 restricts dendritic cells\u2019 ability to break self-tolerance and induce antitumor immunity by regulating IL-12 production and signalling. J Clin Invest. 2006;116(1):90\u2013100.","journal-title":"J Clin Invest"},{"issue":"1","key":"e_1_3_4_120_1","first-page":"61","article-title":"SOCS1 silencing can break high-dose dendritic cell immunotherapy-induced immune tolerance","volume":"1","author":"Hu Q","year":"2008","unstructured":"Hu Q, Qin X, Qian G, et al. SOCS1 silencing can break high-dose dendritic cell immunotherapy-induced immune tolerance. Mol Med Rep. 2008;1(1):61\u201370.","journal-title":"Mol Med Rep"},{"key":"e_1_3_4_121_1","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-09-1507"},{"key":"e_1_3_4_122_1","doi-asserted-by":"publisher","DOI":"10.3892\/ijo.2013.2027"},{"issue":"2","key":"e_1_3_4_123_1","first-page":"1630","article-title":"Silencing of suppressor of cytokine signalling 1 enhances the immunological effect of mucin 1-calreticulin-primed 4T1 cell-treated dendritic cells in breast cancer treatment","volume":"15","author":"Qin S","year":"2018","unstructured":"Qin S, Gao Z, Liu Y, et al. Silencing of suppressor of cytokine signalling 1 enhances the immunological effect of mucin 1-calreticulin-primed 4T1 cell-treated dendritic cells in breast cancer treatment. Oncol Lett. 2018;15(2):1630\u20131638.","journal-title":"Oncol Lett"},{"issue":"3","key":"e_1_3_4_124_1","first-page":"1306","article-title":"Effects of epidermal growth factor receptor fusion protein-pulsed, SOCS1-siRNA-silenced dendritic cells on laryngeal cancer cells","volume":"39","author":"Jiang Q","year":"2018","unstructured":"Jiang Q, Yuan Y, Yi W, et al. Effects of epidermal growth factor receptor fusion protein-pulsed, SOCS1-siRNA-silenced dendritic cells on laryngeal cancer cells. Oncol Rep. 2018;39(3):1306\u20131312.","journal-title":"Oncol Rep"},{"key":"e_1_3_4_125_1","doi-asserted-by":"publisher","DOI":"10.26355\/eurrev_201907_18342"},{"key":"e_1_3_4_126_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2011.12.009"},{"key":"e_1_3_4_127_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-017-3859-3"},{"key":"e_1_3_4_128_1","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.98368"},{"key":"e_1_3_4_129_1","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-15-0305"},{"key":"e_1_3_4_130_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41416-022-01853-z"},{"key":"e_1_3_4_131_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12935-015-0253-6"},{"key":"e_1_3_4_132_1","doi-asserted-by":"publisher","DOI":"10.1021\/mp100067u"},{"key":"e_1_3_4_133_1","doi-asserted-by":"publisher","DOI":"10.1038\/nbt.1564"},{"key":"e_1_3_4_134_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.biomaterials.2014.10.050"},{"issue":"19","key":"e_1_3_4_135_1","doi-asserted-by":"crossref","first-page":"6619","DOI":"10.1039\/D3BM01265D","article-title":"Dual-responsive PEG-lipid polyester nanoparticles for siRNA and vaccine delivery elicit anti-cancer immune responses by modulating tumor microenvironment","volume":"11","author":"Liu Z","year":"2023","unstructured":"Liu Z, Zhao L, Feng Y, et al. Dual-responsive PEG-lipid polyester nanoparticles for siRNA and vaccine delivery elicit anti-cancer immune responses by modulating tumor microenvironment. Biomater Sci. 2023;11(19):6619\u20136634.","journal-title":"Biomater Sci"},{"key":"e_1_3_4_136_1","doi-asserted-by":"publisher","DOI":"10.1039\/D3BM00702B"},{"issue":"7","key":"e_1_3_4_137_1","doi-asserted-by":"crossref","first-page":"2977","DOI":"10.1172\/JCI73174","article-title":"CTLA4 aptamer delivers STAT3 siRNA to tumor-associated and malignant T cells","volume":"124","author":"Herrmann A","year":"2014","unstructured":"Herrmann A, Priceman SJ, Swiderski P, et al. CTLA4 aptamer delivers STAT3 siRNA to tumor-associated and malignant T cells. J Clin Invest. 2014;124(7):2977\u20132987.","journal-title":"J Clin Invest"},{"key":"e_1_3_4_138_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-018-19463-2"},{"issue":"1","key":"e_1_3_4_139_1","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1006\/clin.1995.1051","article-title":"Structural characterization of peptides that bind synovial fluid antibodies from RA patients: a novel strategy for identification of disease-related epitopes using a random peptide library","volume":"75","author":"Dybwad A","year":"1995","unstructured":"Dybwad A, F\u00f8rre O, Natvig JB, et al. Structural characterization of peptides that bind synovial fluid antibodies from RA patients: a novel strategy for identification of disease-related epitopes using a random peptide library. Clin Immunol Immunopathol. 1995;75(1):45\u201350.","journal-title":"Clin Immunol Immunopathol"},{"issue":"6","key":"e_1_3_4_140_1","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1111\/j.1365-3083.1991.tb01605.x","article-title":"Immune responses to 18.6 and 30-kDa mycobacterial antigens in rheumatoid patients, and V beta usage by specific synovial T-cell lines and fresh T cells","volume":"34","author":"Sioud M","year":"1991","unstructured":"Sioud M, Kjeldsen-Kragh J, Quayle AJ, et al. Immune responses to 18.6 and 30-kDa mycobacterial antigens in rheumatoid patients, and V beta usage by specific synovial T-cell lines and fresh T cells. Scand J Immunol. 1991;34(6):803\u2013812.","journal-title":"Scand J Immunol"},{"key":"e_1_3_4_141_1","doi-asserted-by":"publisher","DOI":"10.1096\/fj.02-0280fje"},{"key":"e_1_3_4_142_1","doi-asserted-by":"publisher","DOI":"10.34133\/cbsystems.0468"},{"key":"e_1_3_4_143_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2026.02.015"}],"container-title":["Expert Opinion on Therapeutic Targets"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/14728222.2026.2748740","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.tandfonline.com\/doi\/full-xml\/10.1080\/14728222.2026.2748740","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/14728222.2026.2748740","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T08:56:05Z","timestamp":1791968165000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/14728222.2026.2748740"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,14]]},"references-count":141,"alternative-id":["10.1080\/14728222.2026.2748740"],"URL":"https:\/\/doi.org\/10.1080\/14728222.2026.2748740","relation":{},"ISSN":["1472-8222","1744-7631"],"issn-type":[{"value":"1472-8222","type":"print"},{"value":"1744-7631","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,14]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=iett20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=iett20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2026-05-25","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-10-09","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-10-14","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}